172 related articles for article (PubMed ID: 14640936)
1. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Jendrossek V; Belka C; Bamberg M
Expert Opin Investig Drugs; 2003 Dec; 12(12):1899-924. PubMed ID: 14640936
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
[TBL] [Abstract][Full Text] [Related]
3. [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Pikó B; Bassam A; Nagy KA; Török E; Vághy R; Vargáné Tamás R; Puskásné Szatmári K
Magy Onkol; 2012 Sep; 56(3):166-70. PubMed ID: 23008824
[TBL] [Abstract][Full Text] [Related]
4. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
5. Current chemotherapy for glioblastoma.
Parney IF; Chang SM
Cancer J; 2003; 9(3):149-56. PubMed ID: 12952300
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Kirstein MN; Poquette CA; Tan M; Friedman HS; Brent TP
Clin Cancer Res; 2000 Oct; 6(10):4110-8. PubMed ID: 11051264
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
Nagasawa DT; Chow F; Yew A; Kim W; Cremer N; Yang I
Neurosurg Clin N Am; 2012 Apr; 23(2):307-22, ix. PubMed ID: 22440874
[TBL] [Abstract][Full Text] [Related]
8. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
[TBL] [Abstract][Full Text] [Related]
9. Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Melchardt T; Magnes T; Weiss L; Grundbichler M; Strasser M; Hufnagl C; Moik M; Greil R; Egle A
BMC Complement Altern Med; 2014 Mar; 14():115. PubMed ID: 24679099
[TBL] [Abstract][Full Text] [Related]
10. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Goldwirt L; Beccaria K; Carpentier A; Idbaih A; Schmitt C; Levasseur C; Labussiere M; Milane A; Farinotti R; Fernandez C
J Neurooncol; 2015 Apr; 122(2):273-81. PubMed ID: 25794638
[TBL] [Abstract][Full Text] [Related]
11. [The sodium pump could constitute a new target to combat glioblastomas].
Lefranc F; Mijatovic T; Kiss R
Bull Cancer; 2008 Mar; 95(3):271-81. PubMed ID: 18390407
[TBL] [Abstract][Full Text] [Related]
12. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Johannessen TC; Bjerkvig R
Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
[TBL] [Abstract][Full Text] [Related]
14. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
15. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract][Full Text] [Related]
16. Avastin: more questions than answers. .
Desjardins A; Sampson JH
J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
[No Abstract] [Full Text] [Related]
17. Status quo--standard-of-care medical and radiation therapy for glioblastoma.
Becker KP; Yu J
Cancer J; 2012; 18(1):12-9. PubMed ID: 22290252
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Rovere RK
Klin Onkol; 2014; 27(3):219-20. PubMed ID: 24918282
[TBL] [Abstract][Full Text] [Related]
19. An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
Pawlowska E; Szczepanska J; Szatkowska M; Blasiak J
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562589
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]